| 1 |
NCT03255031 |
Recruiting |
Ketogenic Diet (KD) in Alcoholism |
|
- Dietary Supplement: Ketogenic Diet (KD)
- Dietary Supplement: Standard American (SA) Meals and Shakes
|
Interventional |
Early Phase 1 |
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- To assess ketogenic diet on withdrawal ratings (CIWA) and Benzodiazepine use during withdrawal in the first week of detoxification.
- To assess ketogenic diet on brain function (during rest and activation assessed with fMRI), neurochemistry (assessed with MRS) and structure (assessed with MRI).
- To assess ketogenic diet on NP performance.
- To determine if ketogenic diet improves: 1. sleep. 2. mood. 3. alcohol craving.
|
100 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03255031 |
170152
17-AA-0152 |
|
October 24, 2017 |
December 31, 2020 |
December 31, 2020 |
August 21, 2017 |
April 3, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 2 |
NCT02707055 |
Recruiting |
A Novel Compound for Alcoholism Treatment: A Translational Strategy |
|
- Drug: PF-05190457
- Behavioral: MI-VF
- Other: Placebo
- Other: Counseling
|
Interventional |
Phase 2 |
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- The primary aim will be to determine whether PF-05190457, compared to placebo, reduces alcohol cue-elicited craving.
- To determine whether PF-05190457, compared to placebo, reduces brain blood oxygen level dependent (BOLD) response during exposure to alcohol cues
- To determine whether PF-05190457, compared to placebo, reduces food choices in a virtual buffet conducted in a virtual reality context
|
55 |
All |
18 Years to 65 Years (Adult) |
NCT02707055 |
160080
16-AA-0080 |
|
March 11, 2016 |
December 31, 2018 |
December 31, 2019 |
March 14, 2016 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 3 |
NCT02989493 |
Recruiting |
Testing Doxazosin to Treat Stress Mechanisms in Alcoholism |
|
- Drug: Doxazosin
- Other: Placebo
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Startle potentiation during stress reactivity task
- No heavy drinking days
- Total number of alcoholic drinks
- (and 2 more...)
|
136 |
All |
18 Years to 65 Years (Adult) |
NCT02989493 |
Dox
R01AA024388 |
|
April 12, 2017 |
December 2020 |
December 2020 |
December 12, 2016 |
April 12, 2018 |
|
- University of Wisconsin
Madison, Wisconsin, United States
|
| 4 |
NCT03233802 |
Recruiting |
Individualized Assessment and Treatment for Alcoholism II |
|
- Behavioral: Individualized Assess & Treatment (IATP)
- Behavioral: Packaged Cognitive-Behavioral (PCBT)
- Behavioral: Case Management (CaseM)
|
Interventional |
Not Applicable |
- UConn Health
- Ronald M. Kadden
- Howard Tennen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Proportion of days abstinent (PDA)
- Proportion Heavy Drinking days (PDH)
- Drinker Inventory of Consequences (DrInC) score
|
207 |
All |
18 Years and older (Adult, Senior) |
NCT03233802 |
16-211-3 |
IATP2 |
August 1, 2016 |
July 31, 2020 |
July 31, 2021 |
July 31, 2017 |
August 1, 2017 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States
|
| 5 |
NCT03380728 |
Not yet recruiting |
Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial |
|
- Drug: Ibogaine Hydrochloride
|
Interventional |
Phase 2 |
- University of Sao Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time without using alcohol
- Subjective effects
- Biomarkers
- Cardiovascular effects
|
12 |
All |
18 Years to 65 Years (Adult) |
NCT03380728 |
72938717.3.0000.5440 |
|
March 2018 |
December 2019 |
December 2019 |
December 21, 2017 |
January 5, 2018 |
|
- Ribeirão Preto Medical School
Ribeirão Preto, São Paulo, Brazil
|
| 6 |
NCT00300638 |
Recruiting |
Alcoholism: Emotion and Thinking |
|
- Procedure: Magnetic Resonance Imaging (MRI)
- Behavioral: Interviews, cognitive tests, and emotional measurements
|
Observational |
|
- Boston University
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- VA Office of Research and Development
|
Other / NIH / U.S. Fed |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- Alcoholism's effects on thinking, behavior and brain functioning
|
700 |
All |
25 Years to 76 Years (Adult, Senior) |
NCT00300638 |
H-24686
R01AA007112
K05AA000219 |
|
August 2001 |
May 2020 |
May 2023 |
March 9, 2006 |
March 19, 2018 |
|
- VA Hospital and Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 7 |
NCT02262026 |
Recruiting |
The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism |
|
- Drug: 125 mg AZD0530
- Drug: 50 mg AZD0530
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- BOLD activation during A1 phase
- BOLD signal activation in the anterior cingulate cortex(ACC)
|
90 |
All |
18 Years to 35 Years (Adult) |
NCT02262026 |
1503015528 |
|
November 2014 |
April 28, 2019 |
April 28, 2019 |
October 10, 2014 |
March 16, 2018 |
|
- Hartford Hospital
Hartford, Connecticut, United States
|
| 8 |
NCT02233868 |
Recruiting |
Brain Inflammation and Function in Alcoholism |
|
- Device: MRI
- Drug: C-11PBR28
- Drug: F-18FDG
|
Interventional |
Early Phase 1 |
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- To assess if there is inflammation in the brain of alcoholics as measured with [11C]PBR28 and to determine if it recovers with 3 weeks of detoxification.
- To assess the impact of neuroinflammation on brain function (assessed with PET and 18FDG and with MRI for fMRI with task activation and for functional connectivity).
- To determine if the NP variables correlate with neuroinflammation.
- To determine if the measure of neuroinflammation predicts relapse in AD participants in the 3 month follow-up period.
|
144 |
All |
30 Years to 75 Years (Adult, Senior) |
NCT02233868 |
140192
14-AA-0192 |
|
September 6, 2014 |
December 31, 2021 |
December 29, 2023 |
September 9, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 9 |
NCT02910193 |
Recruiting |
Alcohol Addiction: A Systems-oriented Approach |
|
|
Observational |
|
- Charite University, Berlin, Germany
- Central Institute of Mental Health, Mannheim
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Functional brain imaging assessed using a Siemens Magnetom TimTrio, 3 Tesla
- Structural brain imaging assessed using a Siemens Magnetom TimTrio, 3 Tesla
- Assessment of genetic candidate markers and epigenetic markers of alcohol use disorders
|
168 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02910193 |
01ZX1311E |
eMedAlcohol |
January 2014 |
December 2018 |
December 2018 |
September 21, 2016 |
September 21, 2016 |
|
- Charite - Universitätsmedizin Berlin
Berlin, Germany
|
| 10 |
NCT03058276 |
Recruiting |
New Therapeutic Strategies for Inhibitory Control in Alcoholism |
|
- Behavioral: Retrieval-Extinction Learning
- Other: rTMS
- Other: SAM
|
Interventional |
Not Applicable |
- Hospital Universitario 12 de Octubre
- Ministerio de Sanidad, Servicios Sociales e Igualdad
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Relapses
- Heavy drinking
- Abstinence
- (and 3 more...)
|
105 |
All |
18 Years to 50 Years (Adult) |
NCT03058276 |
2015/099 |
|
January 1, 2016 |
September 2018 |
December 2018 |
February 20, 2017 |
March 13, 2018 |
|
- Hospital Universitario 12 de Octubre
Madrid, Spain
|
| 11 |
NCT02901041 |
Recruiting |
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism |
|
- Drug: Zonisamide
- Behavioral: Take Control
- Drug: Placebo (for Zonisamide)
|
Interventional |
Phase 3 |
- Boston University Charles River Campus
- Mclean Hospital
- University of Houston
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alcohol Consumption
- Risk Task - Risk Taking Behavior
- Cued Go/No-go Task - Impulsivity
- (and 2 more...)
|
100 |
All |
21 Years to 65 Years (Adult) |
NCT02901041 |
2R01AA015923-06 |
|
September 21, 2017 |
February 2021 |
August 2021 |
September 15, 2016 |
January 18, 2018 |
|
- Center for Anxiety and Related Disorders - Boston University
Boston, Massachusetts, United States
|
| 12 |
NCT02616094 |
Recruiting |
Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse |
|
- Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
- Device: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Time to Relapse
- Time to heavy drinking relapse
- Percent of days of alcohol use in follow-up
|
210 |
All |
18 Years to 60 Years (Adult) |
NCT02616094 |
1501015225 |
|
November 2015 |
March 2020 |
December 2020 |
November 26, 2015 |
January 17, 2018 |
|
- Yale Stress Center
New Haven, Connecticut, United States
|
| 13 |
NCT02771925 |
Recruiting |
Treatment for Alcohol Dependence With Gabapentin |
|
- Drug: Gabapentin 2g/day divided in two doses for 24 weeks
- Drug: Placebo 2g/day divided in two doses for 24 weeks
|
Interventional |
Phase 4 |
- Dayanand Medical College and Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Rate of no Heavy Episodic Drinking over 6 month.
- Alcohol Craving
- Change in Quality of Life
- (and 3 more...)
|
200 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02771925 |
TAG2016 |
TAG |
June 2016 |
April 2018 |
May 2018 |
May 13, 2016 |
June 10, 2016 |
|
- Dyanand Medical College and Hospital
Ludhiana, Punjab, India
|
| 14 |
NCT02881424 |
Recruiting |
Study of Familiarity in Alcohol Dependence |
|
|
Observational |
|
- University Hospital, Lille
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Familiarity threshold
- Alcohol consumption
- MocA score
- (and 5 more...)
|
68 |
All |
18 Years to 65 Years (Adult) |
NCT02881424 |
2014_51
2014-A01761-46 |
FALCO |
March 2015 |
April 2018 |
April 2018 |
August 29, 2016 |
April 13, 2018 |
|
- University Hospital, Lille - CSAPA
Lille, France - University Hospital, Lille - Fontan 2
Lille, France
|
| 15 |
NCT03479086 |
Recruiting
New |
Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia |
|
- Drug: Topiramate
- Drug: Naltrexone
|
Interventional |
Phase 3 |
- South West Sydney Local Health District
- National Health and Medical Research Council, Australia
- University of Sydney
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of heavy drinking days, as measured by the Time Line Follow Back
- Time to relapse, as measured by the Time Line Follow Back
- Time to lapse, as measured by the Time Line Follow Back
- (and 12 more...)
|
280 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03479086 |
X16-0231 |
|
June 20, 2017 |
November 1, 2020 |
November 1, 2020 |
March 27, 2018 |
March 27, 2018 |
|
- Drug Health Services, Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
|
| 16 |
NCT02958280 |
Recruiting |
A Tailored Physical Activity Smartphone App for Patients With Alcohol Dependence |
|
- Other: App Development and Open Pilot
|
Interventional |
Not Applicable |
- Butler Hospital
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Minutes of moderate-to-vigorous physical activity per week
- Satisfaction with App
- App Usage
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT02958280 |
1604-003
R21AA024295 |
|
November 2016 |
September 2018 |
September 2018 |
November 8, 2016 |
January 23, 2018 |
|
- Butler Hospital
Providence, Rhode Island, United States
|
| 17 |
NCT02315885 |
Recruiting |
Biomarkers to Measure Treatment Response for Alcohol Dependence |
|
- Other: Alcohol administration
|
Observational |
|
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- Validity of using serotonin transporter mRNA expression levels in 5 HTTLPR:LL and rs 25531:AA genotype carriers, as a biomarker of alcohol consumption levels.
|
36 |
All |
21 Years to 65 Years (Adult) |
NCT02315885 |
HP-00060091 |
|
July 2015 |
May 2018 |
September 2018 |
December 12, 2014 |
August 18, 2017 |
|
- CNC
Columbia, Maryland, United States
|
| 18 |
NCT02061293 |
Recruiting |
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence |
|
- Drug: Psilocybin
- Drug: Diphenhydramine
- Behavioral: Motivational Enhancement and Taking Action (META)
|
Interventional |
Phase 2 |
- New York University School of Medicine
- Heffter Research Institute
- University of New Mexico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- percent heavy drinking days
- Changes in vital signs
- adverse events
- (and 8 more...)
|
180 |
All |
25 Years to 65 Years (Adult) |
NCT02061293 |
14-00614
Heffter 113080-2 |
|
June 2014 |
October 2019 |
January 2020 |
February 12, 2014 |
April 13, 2018 |
|
- University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States - Clinical and Translational Science Institute, NYU Langone Medical Center
New York, New York, United States
|
| 19 |
NCT03152760 |
Recruiting |
Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study |
|
|
Observational |
|
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- The Peter G. Dodge Foundation (PGDF)
- National Institutes of Health Clinical Center (CC)
|
NIH / Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- To investigate the differences in the gut microbiota in abstinence and current drinking populations with AUD, by analyzing and comparing the gut microbiota of abstinent AUD participants, Abstinent Group to that of a group of currently drinking A...
- To examine whether participants' gut microbiota composition is associated with biobehavioral correlates as alcohol cue-induced craving during a Cue-reactivity procedure.
|
69 |
All |
21 Years to 65 Years (Adult) |
NCT03152760 |
170093
17-AA-0093 |
|
August 28, 2017 |
December 31, 2020 |
December 31, 2020 |
May 15, 2017 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 20 |
NCT03028662 |
Recruiting |
New Therapeutic Strategies for the Treatment of Alcohol Use Disorders |
|
- Behavioral: Retrieval-Extinction Learning
|
Interventional |
Not Applicable |
- Gabriel Rubio Valladolid, MD
- Hospital Universitario 12 de Octubre
- Instituto de Salud Carlos III
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference between pattern of brain connectivity after training-extinction and basal level
- Number of relapses during 3 months after training-extinction
- Difference between plasma levels of BDNF after training-extinction and basal level
- (and 2 more...)
|
115 |
All |
18 Years and older (Adult, Senior) |
NCT03028662 |
2015-00463 |
|
January 2016 |
September 2018 |
December 2018 |
January 23, 2017 |
March 13, 2018 |
|
- Hospital Universitario 12 de Octubre
Madrid, Spain
|
| 21 |
NCT02316574 |
Recruiting |
The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving |
|
- Behavioral: Cognitive Behavioral Coping Skills Therapy
|
Interventional |
Not Applicable |
- New York State Psychiatric Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Percent heavy drinking days
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02316574 |
#6859 |
FRAME |
December 2014 |
January 2019 |
January 2019 |
December 15, 2014 |
October 27, 2017 |
|
- NYPInstitute
New York, New York, United States
|
| 22 |
NCT03120468 |
Recruiting |
Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder |
|
- Drug: Topiramate and N-Acetyl Cysteine
- Drug: Topiramate and Placebo
|
Interventional |
Early Phase 1 |
- Nassima Ait-Daoud Tiouririne
- University of Virginia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Cognitive side effects
- Percent Heavy Drinking Days (PHDD)
- Drinks per Drinking Day
- (and 4 more...)
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT03120468 |
19422 |
|
May 1, 2017 |
April 2018 |
April 2018 |
April 19, 2017 |
June 19, 2017 |
|
- UVA Center for Leading Edge Addiction Research
Charlottesville, Virginia, United States
|
| 23 |
NCT02723383 |
Recruiting |
Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU |
|
- Drug: BACLOFEN
- Drug: PLACEBO
|
Interventional |
Phase 3 |
- Nantes University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Occurrence (yes or no) of agitation-related adverse events
- Adverse event (yes or no) related to agitation
- Extubation failure defined as reintubation
- (and 11 more...)
|
314 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02723383 |
RC15_0036 |
BACLOREA |
June 2016 |
July 2018 |
July 2018 |
March 30, 2016 |
January 18, 2017 |
|
- CHU ANGERS - réanimation chirurgicale
Angers, France - CHD La Roche Sur YON
La Roche Sur Yon, France - CHU MONTPELLIER - Lapeyronie
Montpellier, France - (and 9 more...)
|
| 24 |
NCT01749215 |
Recruiting |
A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD |
- Alcohol Dependence
- Posttraumatic Stress Disorder (PTSD)
|
- Drug: Topiramate
- Drug: placebo
|
Interventional |
Phase 4 |
- University of California, San Francisco
- United States Department of Defense
- San Francisco Veterans Affairs Medical Center
- Northern California Institute of Research and Education
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in alcohol use as assessed by the Alcohol Timeline Followback (TLFB)
- Change in PTSD symptom severity as assessed by the PTSD Checklist (PCL)
- Change in impulsivity as assessed by Delay Discounting
- (and 2 more...)
|
150 |
All |
18 Years to 65 Years (Adult) |
NCT01749215 |
PT110423
W81XWH-11-PHTBI-BAPHA |
TAP2 |
February 2013 |
October 2017 |
October 2017 |
December 13, 2012 |
October 27, 2016 |
|
- San Francisco VA Medical Center
San Francisco, California, United States
|
| 25 |
NCT02231840 |
Recruiting |
Unit and Clinic Evaluation, Screening, Assessment, and Management |
|
|
Observational |
|
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Obtain phenotypic assessments
|
7500 |
All |
18 Years and older (Adult, Senior) |
NCT02231840 |
140181
14-AA-0181 |
|
September 3, 2014 |
April 29, 2024 |
March 31, 2034 |
September 4, 2014 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 26 |
NCT03060772 |
Recruiting |
A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study) |
|
|
Interventional |
Phase 2 |
- Emory University
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in phagocytic index
- Change in nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)
- Change in alveolar macrophage oxidative stress
- (and 6 more...)
|
36 |
All |
18 Years to 60 Years (Adult) |
NCT03060772 |
IRB00071908
1R01AA025857 |
APPEAL |
January 3, 2018 |
March 20, 2019 |
March 20, 2019 |
February 23, 2017 |
January 9, 2018 |
|
- Atlanta VA Medical Center
Decatur, Georgia, United States
|
| 27 |
NCT02438969 |
Recruiting |
Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence |
- Fear
- Stress
- Alcohol Dependence
|
|
Observational |
|
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- The primary objective of the study is to evaluate the role and interaction of epigenetic/genetic factors, ELS exposure, and AUD on neuronal mechanisms of fear conditioning and extinction.
- Explore the genetic variants and epigenetic factors on fear extinction in AUD and non-AUD participants with or without ELS; examine the differences in reward and emotion processing, and neural response to alcohol; and examine the relationship be...
|
120 |
All |
21 Years to 65 Years (Adult) |
NCT02438969 |
150127
15-AA-0127 |
|
May 5, 2015 |
December 30, 2019 |
December 30, 2020 |
May 8, 2015 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 28 |
NCT02711189 |
Not yet recruiting |
Oxytocin in Alcohol Use Disorder |
|
- Drug: Oxytocin
- Other: Placebo
|
Interventional |
Phase 1 |
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Alcohol Craving, Self-Administration
- Stimulation Sedation; Cognitive Performance
- BOLD response cognitive tasks and cues
|
32 |
Male |
21 Years to 55 Years (Adult) |
NCT02711189 |
160082
16-AA-0082 |
|
March 8, 2016 |
November 24, 2018 |
November 24, 2019 |
March 17, 2016 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 29 |
NCT02409888 |
Recruiting |
Evaluating Interventions for Alcohol Use Disorder |
|
- Behavioral: Motivational Enhancement Therapy
- Behavioral: Cognitive Behavioral Therapy
- Other: FC Assessment
- Other: IB Assessment
|
Interventional |
Not Applicable |
- Rutgers, The State University of New Jersey
- Syracuse University
- Pacific Institute for Research and Evaluation
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02409888 |
Pro2013003944
1R01AA022330-01A1 |
|
November 2015 |
February 2019 |
July 2019 |
April 7, 2015 |
August 4, 2017 |
|
- Rutgers University School of Public Health
New Brunswick, New Jersey, United States
|
| 30 |
NCT02690987 |
Recruiting |
Gut Hormones in Obesity, Nicotine and Alcohol Dependence |
- Obesity
- Smoking Cessation
- Alcoholism
|
- Drug: Exenatide
- Biological: Desacyl ghrelin
- Biological: Saline
|
Interventional |
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Functional MRI measure of brain activation during cigarette, alcohol and food picture evaluation task
- Functional MRI measure of brain activation during anticipation of winning monetary reward (monetary incentive delay task)
- Functional MRI measure of brain activation during negative emotional reactivity task
- (and 3 more...)
|
95 |
All |
18 Years to 60 Years (Adult) |
NCT02690987 |
15/LO/1041
MR/M007022/1 |
GHADD |
August 2015 |
October 2018 |
October 2018 |
February 24, 2016 |
December 22, 2017 |
|
- Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, Hammersmith Hospital
London, United Kingdom
|
| 31 |
NCT03338361 |
Recruiting |
Research on the Efficacy of the "T.O.P. Computer Training" Procedure in the Treatment of Alcohol Dependence |
|
- Behavioral: active approach avoidance training and sham visual probe training
- Behavioral: sham approach avoidance training and active visual probe training
- Behavioral: active approach avoidance training and active visual probe training
- Behavioral: sham approach avoidance training and sham visual probe training
|
Interventional |
Not Applicable |
- University Ghent
- PZ Heilig Hart
- PZ Sint-Camillus
- University of Amsterdam
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- change in drink behavior
- change in Retraining attentional bias
- change in Retraining action tendencies
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT03338361 |
EC/2017/1079 |
|
October 24, 2017 |
November 2019 |
November 2019 |
November 9, 2017 |
November 9, 2017 |
|
- University Ghent
Ghent, Belgium
|
| 32 |
NCT01847469 |
Recruiting |
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence |
- Alcohol Dependence
- Post-Traumatic Stress Disorder (PTSD)
|
- Behavioral: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)
- Drug: Zonisamide
- Drug: Placebo
|
Interventional |
Phase 2 |
- Yale University
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Timeline Follow-Back (TLFB)assessment
- Change in Clinicians Administered PTSD Scale (CAPS)
|
30 |
All |
21 Years to 65 Years (Adult) |
NCT01847469 |
1211011063
01641 |
|
June 2013 |
October 2019 |
October 2019 |
May 6, 2013 |
March 15, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
| 33 |
NCT02371889 |
Recruiting |
A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers |
|
- Drug: Topiramate
- Behavioral: Medical Management
- Drug: Inactive Placebo
|
Interventional |
Phase 2 |
- University of Pennsylvania
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health (NIH)
- (and 2 more...)
|
Other / NIH / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Frequency of Heavy Drinking Days Per Week by Medication and Genotype Group (timeline follow back calendar).
- Frequency of positive expectancies regarding alcohols positive effects and level of confidence in resisting heavy drinking by Medication and Genotype Group (daily questionnaire).
|
200 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02371889 |
821035
R01AA023192 |
TOPG |
January 2015 |
November 2020 |
January 2021 |
February 26, 2015 |
October 5, 2017 |
|
- Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania, United States - University of Pennsylvania Treatment Research Center
Philadelphia, Pennsylvania, United States
|
| 34 |
NCT03341715 |
Not yet recruiting |
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN |
- Familial Alcoholism Vulnerability
|
- Drug: Mavoglurant (AFQ056)
- Other: Placebo
|
Interventional |
Early Phase 1 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- MRI Monetary Incentive Delay (MID) task
- MRI Alcohol Cue Reactivity (ACR) task
|
14 |
All |
18 Years to 35 Years (Adult) |
NCT03341715 |
HHC-2017-0172 |
|
January 17, 2018 |
October 31, 2018 |
November 30, 2018 |
November 14, 2017 |
January 9, 2018 |
|
- Hartford Hospital
Hartford, Connecticut, United States
|
| 35 |
NCT02364817 |
Recruiting |
ADHD: Gaps Between Patients With Alcohol-dependence and Impact on Relapse |
- Alcoholism
- Attention Deficit Disorder With Hyperactivity
|
- Behavioral: cognitive and psychiatric assessment
|
Observational |
|
- University Hospital, Lille
- Institute for Scientific Research on Beverages (France)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cumulated rate of alcohol relapse
- Psychometric properties of the ASRS
- Multivariate analysis of the alcohol relapse
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT02364817 |
2013_09
2014-A00132-45 |
AGADIR |
January 2015 |
July 2019 |
July 2019 |
February 18, 2015 |
April 18, 2018 |
|
- Department of Addiction Medicine
Lille, France - Department of Addiction Medicine
Saint-Amand-les-Eaux, France
|
| 36 |
NCT03232112 |
Recruiting |
Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? |
- Alcohol Dependence, in Remission
- Addiction, Alcohol
|
- Drug: Exenatide 2 MG Injection
- Drug: BD PosiFlush (saline)
|
Interventional |
Phase 2 |
- Anders Fink-Jensen, MD, DMSci
- The Novavì outpatient clinics, Copenhagen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Heavy drinking days
- Total alcohol consumption
- Penn Alcohol Craving Scale (PACS) score
- (and 18 more...)
|
139 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03232112 |
EXALT study |
EXALT |
July 12, 2017 |
July 1, 2019 |
July 1, 2019 |
July 27, 2017 |
February 26, 2018 |
|
- Novavì ambulatorierne
Copenhagen, Frederiksberg, Denmark
|
| 37 |
NCT03175549 |
Recruiting |
Medication Development in Alcoholism: Apremilast Versus Placebo |
|
- Drug: Apremilast
- Drug: Placebo
|
Interventional |
Phase 2 |
- The Scripps Research Institute
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT03175549 |
U01AA025476 |
|
November 1, 2017 |
December 2019 |
December 2019 |
June 5, 2017 |
April 6, 2018 |
|
- The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research
La Jolla, California, United States
|
| 38 |
NCT02187211 |
Recruiting |
Minocycline's Effects on Alcohol Responses in Humans |
|
- Drug: Minocycline
- Drug: Placebo (for Minocycline)
|
Interventional |
Phase 1 |
- Yale University
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Biphasic Alcohol Effects Scale (BAES)
|
60 |
All |
21 Years to 50 Years (Adult) |
NCT02187211 |
1312013129 |
|
July 2015 |
July 2018 |
July 2018 |
July 10, 2014 |
January 17, 2018 |
|
- VA Connecticut Healthcare System
West Haven, Connecticut, United States
|
| 39 |
NCT02247388 |
Recruiting |
Automated Bilingual Computerized Alcohol Screening and Intervention in Latinos (AB-CASI) |
|
- Behavioral: Computerized Alcohol Screening
- Behavioral: Brief Negotiated Interview
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Self Reported Binge Drinking Episodes
- Mean Number of Weekly Drinks
- Alcohol-Related Negative Health Behaviors and Consequences
|
820 |
All |
18 Years and older (Adult, Senior) |
NCT02247388 |
1211011052 |
AB-CASI |
October 2014 |
August 2019 |
August 2019 |
September 25, 2014 |
March 10, 2017 |
|
- Bridgeport Hospital
Bridgeport, Connecticut, United States
|
| 40 |
NCT02564991 |
Recruiting |
Study of Structural Imaging |
|
|
Observational |
|
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- The Primary outcome of this study is to assess recovery of cerebellar structure and function at the end of treatment compared to treatment entry measures.
|
250 |
All |
30 Years to 60 Years (Adult) |
NCT02564991 |
150203
15-AA-0203 |
|
September 30, 2015 |
June 22, 2020 |
September 30, 2020 |
October 1, 2015 |
April 19, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 41 |
NCT02888002 |
Recruiting |
Internet-based vs Face-to-face Treatment for Alcohol Dependence |
- Alcohol Abuse
- Alcohol Dependence
- Harmful Alcohol Use
- Alcohol Use Disorder
|
- Behavioral: Guide to better alcohol habits
|
Interventional |
Not Applicable |
- Karolinska Institutet
- Stockholm County Council, Sweden
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time Line Follow Back (TLFB)
- Time Line Follow Back (TLFB) Change in number of consumption days
- Time Line Follow Back (TLFB) Change in number of days binge-drinking days
- (and 6 more...)
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02888002 |
2014/1758-31/2-2 |
IMS |
November 2015 |
February 2019 |
February 2019 |
September 2, 2016 |
September 2, 2016 |
|
- Karolinska Institutet, Department of Public Health Sciences
Stockholm, Sweden
|
| 42 |
NCT01842503 |
Recruiting |
Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent |
|
- Drug: GET 73
- Drug: inactive ingredients capsule
|
Interventional |
Phase 1
Phase 2 |
- Laboratorio Farmaceutico Ct S.r.l.
- Voisin Consulting, Inc.
- Latis Srl
- Quotient Bioresearch Ltd
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- changes in area under the plasma concentration of alcohol versus time curve (AUC), after administration of GET 73 or placebo
- Changes in pleasurable and negative effects of alcohol intoxication and sedation, measured by the Biphasic Alcohol Effects Scales (BAES),during the Alcohol Self-Administration (ASA) session, when taking GET 73 compared to placebo.
- Changes in reaction time, measured by Conners's Continuous Performance Task (CPT),when taking GET 73 compared to placebo
- (and 10 more...)
|
25 |
All |
21 Years to 65 Years (Adult) |
NCT01842503 |
73CT-2-03
2012-005515-13 |
SPAD |
November 2014 |
November 2017 |
November 2017 |
April 29, 2013 |
September 5, 2017 |
|
- Roger Williams Medical Center
Providence, Rhode Island, United States
|
| 43 |
NCT02824354 |
Not yet recruiting |
Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. |
- Cirrhosis
- Alcohol Dependence
- Nalmefene
|
- Drug: Nalmefene (Selincro®) 18 mg tablet
- Drug: placebo
|
Interventional |
Phase 3 |
- Centre Hospitalier Universitaire, Amiens
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Reduction of the number of monthly heavy drinking days after 6 months of treatment compared to baseline.
- The number of non-drinking days during the treatment period; nalmefene arm versus placebo arm,
- Evaluation of craving; nalmefene arm responders versus nalmefene arm non-responders
- (and 2 more...)
|
250 |
All |
18 Years and older (Adult, Senior) |
NCT02824354 |
PI2015_843_0017 |
NalmeCir |
July 2016 |
December 2018 |
December 2018 |
July 6, 2016 |
July 6, 2016 |
|
|
| 44 |
NCT02377726 |
Recruiting |
Anonymous Treatment on the Internet for Alcohol Dependence: A Randomised, Controlled Trial |
- Alcohol Abuse
- Alcohol Dependence
- Harmful Alcohol Use
- Alcohol Use Disorder
|
- Behavioral: Alkoholhjälpen counselor support
- Behavioral: eChange Alkoholhjälpen
- Behavioral: Alkoholhjälpen
|
Interventional |
Not Applicable |
- Karolinska Institutet
- Public Health Agency of Sweden
- Center for Psychiatry Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time Line Follow Back (TLFB) (Change in total in consumption of alcohol last 7 days)
- Time Line Follow Back (TLFB) (Change in number of standard drinks per day during last 7 days)
- Time Line Follow Back (TLFB) (Change in number of consumption days during last 7 days)
- (and 9 more...)
|
2400 |
All |
18 Years and older (Adult, Senior) |
NCT02377726 |
2014/1758-31-2 |
|
April 2015 |
March 2017 |
March 2019 |
March 4, 2015 |
August 30, 2016 |
|
- Karolinska Institutet, Department of Public Health Sciences
Stockholm, Sweden
|
| 45 |
NCT03493958 |
Not yet recruiting
New |
RCT of Web-Based Behavioral Sleep Intervention for Individuals With Alcohol Use Disorder |
|
- Behavioral: SHUTi
- Other: insomnia education web-based program
|
Interventional |
Phase 1
Phase 2 |
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary outcome measures include changes in insomnia severity over time and changes in actigraphy-recorded sleep efficiency over time.
|
79 |
All |
18 Years to 65 Years (Adult) |
NCT03493958 |
180079
18-CC-0079 |
|
April 27, 2018 |
August 1, 2019 |
December 1, 2019 |
April 11, 2018 |
April 24, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 46 |
NCT02187224 |
Recruiting |
Progesterone Effect on Individuals Diagnoses With AD and PTSD. |
- Alcohol Dependence
- Post-Traumatic Stress Disorder (PTSD)
|
- Drug: Progesterone
- Drug: Placebo (for Progesterone)
|
Interventional |
Phase 2
Phase 3 |
- Yale University
- United States Department of Defense
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Visual Analogue Scale - Craving (VASC)
- State Trait Anxiety Inventory (STAI-6)
|
34 |
All |
18 Years to 45 Years (Adult) |
NCT02187224 |
1603017361 |
|
September 2016 |
September 2018 |
September 2018 |
July 10, 2014 |
November 24, 2017 |
|
- VA Connecticut Healtcase System
West Haven, Connecticut, United States
|
| 47 |
NCT03190356 |
Recruiting |
Soberlink - MAP Outcomes Study Protocol |
|
- Device: Soberlink Cellular Device
|
Observational |
|
- Soberlink Healthcare LLC
- MAP Health Management LLC
|
Industry / Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
30 |
All |
21 Years to 65 Years (Adult) |
NCT03190356 |
SLMAPPROT-2017-001 |
|
August 22, 2017 |
November 15, 2017 |
November 15, 2017 |
June 16, 2017 |
August 23, 2017 |
|
- MAP Health Management LLC
Austin, Texas, United States
|
| 48 |
NCT03278821 |
Recruiting |
The Self Match Study: A Study of Informed Choice in the Treatment of Addiction |
|
- Behavioral: Self Match
- Behavioral: Ekspert Match
|
Interventional |
Not Applicable |
- Kjeld Andersen
- University of Southern Denmark
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Reduced amount of drinking days measured by Time Line Follow Back.
- Compliance measured by proportion of patients who has completed treatment.
- Quality of life measured by WHO's Quality of Life scale.
- (and 2 more...)
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT03278821 |
RESCueH, The Self Match Study |
|
May 1, 2017 |
May 1, 2019 |
January 29, 2021 |
September 12, 2017 |
September 12, 2017 |
|
- RESCueH alcohol Studies, Unit of Clinical Alcohol Research, Psyciatric Research Unit, Clinical Institute, University of Southern Denmark
Odense, Denmark
|
| 49 |
NCT03056365 |
Recruiting |
Advanced Nurses vs. General Practitioners for the Management of Outpatient Alcohol Detox: a Safety and Cost Comparison |
|
- Procedure: Advanced Nurse (AN)
- Procedure: General Practitioner (GP)
|
Interventional |
Not Applicable |
- University Hospital, Lille
- Ministry of Health, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Number of patients considered in failure of outpatient alcohol detoxification period
- The total costs for each arm by cost-minimization
- Number of patients reporting at least one recovery in alcohol consumption
- (and 2 more...)
|
1262 |
All |
18 Years to 64 Years (Adult) |
NCT03056365 |
2015_09
2015-A01936-43
PREPS_14-0209 |
SAMBA |
January 1, 2017 |
January 1, 2019 |
June 1, 2019 |
February 17, 2017 |
February 19, 2018 |
|
- CH Beziers
Beziers, France - CH Boulogne
Boulogne, France - CHU Brest
Brest, France - (and 23 more...)
|
| 50 |
NCT02948296 |
Recruiting |
Charleston ARC Clinical Project 4- Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues |
|
- Device: medial prefrontal cortex
- Device: dorsolateral prefrontal cortex
- Device: sham stimulation
|
Interventional |
Not Applicable |
- Medical University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Percent signal change in the cortex directly stimulated
- Changes in neurochemistry
|
66 |
All |
21 Years to 40 Years (Adult) |
NCT02948296 |
ARC4 |
ARC4 |
January 2016 |
October 2021 |
October 2021 |
October 28, 2016 |
October 28, 2016 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
Create an RSS feed from your search for:
Download the search results for: